Upbeat data on cancer treatment leads to gains for Bluebird Bio

December 16, 2017 at 5:16PM

Good results: Bluebird Bio Inc. gained 18 percent to $201.80 Monday after a series of bullish notes following its presentation of upbeat data on a cancer treatment called chimeric antigen receptor T-cell therapy, or CAR-T. Shares closed the week at $xxx.xx.

Cloud lift: Shares of Symantec Corp. rose 4.4 percent to $29.22 Monday after it was announced that the firm's major cloud security components would now be available on the Oracle Cloud Marketplace. Shares closed Friday at $xx.xx.

No deal bounce: Cable TV and entertainment company Comcast rose 2.8 percent to $39.51 Tuesday after the Wall Street Journal reported it was no longer in talks to buy parts of 21st Century Fox. Shares closed Friday at $xx.xx.

Apple seeds: Finisar climbed 30 percent to $25.14 Wednesday after Apple said it will invest $390 million in the fiber optic component supplier so it can make more lasers used in facial recognition technology. Finisar will use the money to reopen a 700,000-square-foot plant in Sherman, Texas. Shares closed the week at $xx.xx.

about the writer

about the writer